Motif Neurotech, a leader in minimally-invasive bioelectronics for mental health, has secured $18.75 million in a Series A funding round led by Arboretum Ventures, with participation from KdT Ventures, Satori Neuro, and Dolby Family Ventures, along with existing backers Divergent Capital and PsyMed Ventures. The funding will support Motif’s innovative DOT microstimulator, offering a targeted and potentially more effective treatment option for Treatment-Resistant Depression (TRD). The DOT microstimulator, implanted through a minimally-invasive outpatient procedure, aims to stimulate specific brain circuits linked to depression, providing hope for millions struggling with TRD.
Motif Neurotech, a pioneer in minimally-invasive bioelectronics for mental health, announced today an impressive $18.75 million Series A funding round. Led by Arboretum Ventures, the investment saw participation from prominent players like KdT Ventures, Satori Neuro, and Dolby Family Ventures, alongside existing supporters Divergent Capital and PsyMed Ventures.
– Motif Neurotech’s innovative approach represents a potential paradigm shift in mental health treatment. By leveraging the power of bioelectronics, they aim to offer a safer, more targeted, and potentially more effective option for patients suffering from TRD.
Hope for Millions Struggling with TRD
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
TRD, a form of major depressive disorder unresponsive to traditional medications, affects millions worldwide. It can be a debilitating condition, leaving patients feeling hopeless and isolated. Motif’s DOT microstimulator offers a glimmer of hope, designed to precisely stimulate specific brain circuits linked to depression, restoring healthy activity and alleviating symptoms.
Precision Stimulation for Healthy Brain Circuitry
The DOT microstimulator is a pea-sized marvel, implanted during a minimally-invasive 20-minute outpatient procedure. It wirelessly transmits stimulation signals, allowing for at-home therapy and personalized treatment adjustments. This innovative approach offers several advantages over traditional deep brain stimulation (DBS) techniques:
- Minimally invasive: No bulky electrodes or wires, reducing potential complications.
- Precise stimulation: Targets specific brain circuits, minimizing side effects.
- Wireless and rechargeable: Convenient for patients and adaptable to individual needs.
Expansion Plans
The Series A funding empowers Motif to:
- Advance clinical development: Conduct large-scale studies to validate the DOT microstimulator’s efficacy and safety.
- Refine the technology: Enhance the device’s functionality and user experience.
- Scale production and distribution: Make the DOT microstimulator accessible to more patients with TRD.
“This investment is a testament to the immense potential of our technology to revolutionize the treatment of TRD,” said Jacob Robinson, CEO & Founder of Motif Neurotech. “We are incredibly grateful for the support of our investors and excited to bring hope and relief to millions suffering from this debilitating condition.”
Source:Bio Space
